This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Avapritinib for treating advanced systemic mastocytosis

Authoring team

Advanced systemic mastocytosis is a rare, KIT D816V-driven haematologic neoplasm characterized by mast cell infiltration and shortened survival (1).

  • is a rare myeloid neoplasm, driven by the KIT D816V mutation in >90% of patients (2)
  • the increased proliferation and accumulation of neoplastic mast cells, leads to severe, debilitating and often unpredictable symptoms and poor quality of life (QoL)
  • characterized by proliferation and accumulation of mast cells in the bone marrow, skin, and visceral organs
    • mast cell infiltration leads to organ damage, referred to as ‘C-findings’ (that is, cytopenias or liver dysfunction), with limited treatment options and poor survival (1)

Avapritinib

  • is a highly selective inhibitor of the KIT D816V mutation

NICE states that (3):

  • avapritinib is recommended, within its marketing authorisation, as an option for treating advanced systemic mastocytosis (including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm and mast cell leukaemia) in adults

Reference:

  1. Gotlib J et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021 Dec;27(12):2192-2199.
  2. Reiter A et al. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Adv. 2022 Nov 8;6(21):5750-5762.
  3. NICE (November 2024). Avapritinib for treating advanced systemic mastocytosis

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.